The NeurologyLive® Narcolepsy Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with the sleep disorder.
April 23rd 2025
The director of sleep medicine at Nemours Children's Health in Florida talked about the growing role of multidisciplinary care and novel therapies in managing pediatric sleep disorders.
FAERS Data Analysis Reveals Insights on Safety Profiles of Narcolepsy Treatments
February 23rd 2025A recent analysis identified potential safety concerns associated with pitolisant, sodium oxybate, solriamfetol, and modafinil, highlighting distinct adverse event profiles for each narcolepsy treatment.
Hypertension Risk Elevated in Normotensive Patients With Narcolepsy Starting Sodium Oxybate
February 22nd 2025Normotensive patients with narcolepsy on sodium oxybate had over 50% of a higher risk of new-onset hypertension or antihypertensive medication use compared with nonusers of the treatment.
Cognitive Behavioral Therapy-Insomnia Demonstrates Effectiveness in Improving Cancer-Related Fatigue
January 31st 2025Cognitive behavioral therapy for insomnia, a multicomponent psychotherapy, consists of sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Meta-Analysis Confirms Efficacy of Sodium Oxybate in Managing Narcolepsy Symptoms
January 26th 2025Recent findings from an analysis showed that sodium oxybate significantly reduced narcolepsy symptoms, including cataplexy and excessive daytime sleepiness, among patients with the sleep disorder.
Therapeutic Potential of Orexin Agonist ALKS 2680 on Display at SLEEP 2024
June 15th 2024Ron Grunstein, MD, PhD, head of Sleep and Circadian Research at the Woolcock Institute of Medical Research, provided commentary on early, promising data regarding investigational agent ALKS 2680 in patients with narcolepsy type 1.
Understanding the Root of REM Behavior Disorder and Other Parasomnias
May 8th 2024Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, provided commentary on a session chaired at AAN 2024 assessing the diagnostic criteria and treatment options of parasomnias in adults.